The Incidence of Graves’ Hyperthyroidism Before and After COVID-19 Messenger RNA Vaccination
Authors' conclusion
There was no increase in new-onset GD after COVID-19 vaccination. Median free T4 was higher in patients with PVGD, but this was not statistically significant.
Study context
- Population
- Patients carrying diagnoses of GD at a single academic center
- Participants
- 803 vs 901
- Exposure
- Incidence of new-onset GD before vs after introduction of COVID-19 vaccination
- Prevaccinationn = 803reference
- Postvaccinationn = 901
- Outcome
- Incidence of new-onset GD
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
New-onset GD
Prevaccination
131
events
Postvaccination
138
events
P = 0.52
Observational data: associations, not effects.
Further findings
- Median free T4, PVGD vs controls — Median free T4 higher in PVGD (not statistically significant) · higher in PVGD, not statistically significant
- 3.9 vs 2.5 ng/dL · P = 0.05
PVGD among newly diagnosed GD after COVID-19 vaccination
- Newly diagnosed patients in the post-COVID-19 group meeting PVGD criteria
- 24 of 138
Age, gender, race, antibody titers, type of vaccination, PVGD vs controls
- No differences in age, gender, race, antibody titers or type of vaccination between PVGD and controls
Original publication
The Incidence of Graves’ Hyperthyroidism Before and After COVID-19 Messenger RNA Vaccination. Endocr Pract. Published 29 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →